Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV

Tomoko Tadokoro; Asahiro Morishita; Koji Fujita; Kyoko Oura; Teppei Sakamoto; Takako Nomura; Joji Tani; Hirohito Yoneyama; Tsutomu Masaki

doi:10.2169/internalmedicine.9744-17

This article has now been updated. Please use the final version.

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV

Tomoko Tadokoro, Asahiro Morishita, Koji Fujita, Kyoko Oura, Teppei Sakamoto, Takako Nomura, Joji Tani, Hirohito Yoneyama, Tsutomu Masaki

Author information

Tomoko Tadokoro
Department of Gastroenterology and Neurology, Kagawa University, Japan
Asahiro Morishita
Department of Gastroenterology and Neurology, Kagawa University, Japan
Koji Fujita
Department of Gastroenterology and Neurology, Kagawa University, Japan
Kyoko Oura
Department of Gastroenterology and Neurology, Kagawa University, Japan
Teppei Sakamoto
Department of Gastroenterology and Neurology, Kagawa University, Japan
Takako Nomura
Department of Gastroenterology and Neurology, Kagawa University, Japan
Joji Tani
Department of Gastroenterology and Neurology, Kagawa University, Japan
Hirohito Yoneyama
Department of Gastroenterology and Neurology, Kagawa University, Japan
Tsutomu Masaki
Department of Gastroenterology and Neurology, Kagawa University, Japan

Keywords: Case reports, hepatitis C, ledipasvir and sofosbuvir, drug eruption, steroid

JOURNAL OPEN ACCESS Advance online publication

Article ID: 9744-17

DOI https://doi.org/10.2169/internalmedicine.9744-17

The final version of this article is now available: Vol. 57 (2018), No. 8 pp. 1101-1104

Details

Abstract

Combination therapy with ledipasvir and sofosbuvir (LDV/SOF), direct-acting antiviral agents, is highly effective against hepatitis C virus genotype 1 infection. Although LDV/SOF is safer than conventional treatment, reports have indicated that LDV/SOF was discontinued in certain cases due to severe skin disorders. A 68-year-old woman presented with a rash after starting LDV/SOF treatment. We interrupted LDV/SOF and began the oral administration of prednisolone (PSL). After the rash improved, we re-started LDV/SOF with PSL. After treatment, the rash clearly improved; we checked for a sustained virologic response 12 weeks after treatment. Steroids may therefore be an effective treatment option for controlling the side effects of LDV/SOF.

Corresponding author

Register with J-STAGE for free!